Day: August 3, 2020

Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020

Written by Customer Service on August 3, 2020. Posted in Public Companies.

AUSTIN, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live audio webcast at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed...

Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences

Written by Customer Service on August 3, 2020. Posted in Public Companies.

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of 2020 on August 13, 2020.Matt Kane, Chief Executive Officer and co-founder of Precision along with Chris Heery, Chief Medical Officer at Precision, will also participate in the following upcoming investor conferences:William Blair Biotech Focus ConferenceDate: August 6, 2020Fireside chat: 12:00 to 12:45 PM EDTBTIG Virtual Biotechnology ConferenceDate: August 10, 2020Fireside chat: 10:30 – 10:55 AM EDTLive webcasts of each presentation will be accessible on the Company’s website, www.PrecisionBiosciences.com, under the Investors & Media...

Plug Power Brings Hydrogen Fuel Cells to Leading UK Supermarket Retailer Asda

Written by Customer Service on August 3, 2020. Posted in Public Companies.

LATHAM, N.Y., Aug. 03, 2020 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a leading provider of zero emission hydrogen engines and fueling solutions enabling e-mobility, is providing UK-based supermarket Asda with hydrogen fuel cell solutions to power the lift truck fleet within the retail giant’s extensive supply chain network.Asda’s partnership with Plug Power includes a purchase order agreement for Plug Power’s full-service GenKey solution, beginning at the UK facility in Skelmersdale. The turnkey solution includes fuel cells, hydrogen fueling equipment, hydrogen and service. This new customer continues Plug Power’s growth in Europe and represents the first deployment at scale of hydrogen fuel cell technology for material handling within the United Kingdom. The effort reduces Asda’s reliance on traditional lead acid batteries...

Antares Pharma and Lunatus Enter Into an Exclusive Distribution Agreement for XYOSTED® in Saudi Arabia and the United Arab Emirates

Written by Customer Service on August 3, 2020. Posted in Public Companies.

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies (“Lunatus”) to distribute and promote the sale of XYOSTED® in Saudi Arabia and the United Arab Emirates (“UAE”). Under the agreement, Antares will be responsible for the supply of fully packaged product to Lunatus and Lunatus will be responsible for submitting and obtaining regulatory approval for XYOSTED® in Saudi Arabia and the UAE as well as marketing, promotion and distribution of XYOSTED® in these two countries.“We believe today’s announcement represents the first step in creating increased brand awareness for XYOSTED in the rest of the world, and look forward to working with our partner Lunatus...

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview

Written by Customer Service on August 3, 2020. Posted in Public Companies.

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020.“We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. We look forward to working with the FDA to determine next steps for the program and we are continuing to evalutate its potential in oncologic indications.”Mr. Shefferman continued, “In addition, we recently announced receipt...

Kyber Data Science Announces $10 Million Series A Financing Round

Written by Customer Service on August 3, 2020. Posted in Public Companies.

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) — Kyber Data Science LLC (“Kyber”), a subsidiary of Cowen Inc. (NASDAQ:COWN) (“Cowen”), today announced a $10 million Series A financing round led by Cowen and Ian McKinnon, founder of Sandia Holdings LLC (“Sandia”). Mr. McKinnon has joined Kyber’s board of directors, effective upon closing of the investment.Kyber is focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations. Most recently, Kyber unveiled a nationally-representative health care claims and electronic medical records data product for the institutional investor that enables timely and accurate analyses across health care subsectors including drug, medical device, diagnostics, and facilities companies. Transaction-level data allow customers to develop...

Africa Mobile Networks (AMN) Extends Gilat’s Contract of Powering Africa’s Largest Satellite Cellular Backhaul Network

Written by Customer Service on August 3, 2020. Posted in Public Companies.

PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces the extension of Gilat’s contract with Africa Mobile Networks (AMN) to power the largest satellite cellular backhaul network in Africa. AMN’s network enabled by Gilat’s technology serves multiple Tier-1 Telcos in over ten countries throughout Africa.“AMN has selected Gilat, due to its superior technology, to further extend Africa’s largest satellite cellular backhaul network constructed by AMN and powered by Gilat’s VSAT technology,” said Michael Darcy, CEO AMN. “We are pleased to contribute to closing the digital divide by furthering the reach of our network to additional countries reaching...

Chronic Wound Care Market to Reach USD 16.36 Billion by 2027; High Prevalence of Diabetic Ulcers will Provide Impetus to Market Growth, says Fortune Business Insights™

Written by Customer Service on August 3, 2020. Posted in Mergers And Acquisitions.

Pune, Aug. 03, 2020 (GLOBE NEWSWIRE) — The global chronic wound care market size is projected to reach USD 16.36 billion by the end of 2027. The increasing investment in the technological integration will open up a huge potential for the growth of the overall market. According to a report published by Fortune Business Insights, titled “Chronic Wound Care Market Size, Share & COVID-19 Impact Analysis, By Type (Diabetic Ulcers, Pressure Ulcers, Venous Ulcers, and Arterial Ulcers), By Product (Advanced Wound Dressings, Wound Care Devices, Active Therapy, and Others), By End User (Hospitals & Wound Care Centers, and Homecare Settings & Others), and Regional Forecast, 2020-2027,” the market was worth USD 10.12 billion in 2019 and will exhibit a CAGR of 6.2% during the forecast period, 2020-2027.https://www.fortunebusinessinsights.com/industry-reports/chronic-wound-care-market-100222The...

CSW Industrials Reports Fiscal First Quarter 2021 Results

Written by Customer Service on August 3, 2020. Posted in Public Companies.

DALLAS, Aug. 03, 2020 (GLOBE NEWSWIRE) — CSW Industrials, Inc. (Nasdaq: CSWI) today reported results for the 2021 fiscal first quarter ended June 30, 2020.Fiscal First Quarter 2021 HighlightsManagement responding decisively to the global pandemic, acting in the best interest of all stakeholdersOperations continue with minimal disruption and ongoing commitment to safeguards for employeesReported revenue from continuing operations of $91.0 million, compared to $102.3 million in the prior year periodReported operating income of $16.3 million, compared to $20.3 million in the prior year period, with no adjustments in either quarterReported earnings per share of $0.81, compared to $1.01 in the prior year period, with no adjustments in either quarterDemand for our products in the HVAC/R and plumbing end markets gained momentum in the...

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on August 3, 2020. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 30,000 shares of Calithera’s common stock, at a per share exercise price of $4.70, the closing trading price on July 31, 2020. One-fourth of the option vests in July 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved...

Day: August 3, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals